HRGN.US Harvard Apparatus Regenerative Technology Inc.

Consumer Defensive Biotechnology USA Stocks
1.98 USD
Close of Nov 14, 2026
0.9600 2.46
Market cap
USD 40.2M
P/E
-
P/B
267.53x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is HRGN.US undervalued?

Graham number

The Graham number of Harvard Apparatus Regenerative Technology Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Harvard Apparatus Regenerative Technology Inc. fundamental analysis

No fundamental analysis for Harvard Apparatus Regenerative Technology Inc. yet.

Harvard Apparatus Regenerative Technology Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Harvard Apparatus Regenerative Technology Inc.

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. The company's lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. It's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged or…

Full company profile